Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Biologics: Targets and Therapy

Volumn 8, Issue , 2014, Pages 155-167

  Davis Ajami, Mary Lynn ^a   Wu, Jun ^b   Downton, Katherine ^c   Ludeman, Emilie ^c   Noxon, Virginia ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Biosimilar; Chronic kidney disease; Epoetin alfa; Erythropoiesis; Renal anemia; Retacrit

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; SB 309; UNCLASSIFIED DRUG;

ANEMIA; ARTERY THROMBOSIS; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG UTILIZATION; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INJECTION SITE REACTION; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; THORAX DISEASE; TREATMENT INDICATION;

EID: 84899132159     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S27578     Document Type: Review

References (107)

1. KDOQI Clinical Practice Guidelines: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease [webpage on the Internet]. New York: National Kidney Foundation; 2006. Available from: http://www. kidney. org/professionals/kdoqi/guidelines_anemia/cpr12. htm. Accessed September 09, 2013.
2. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. New York: National Kidney Foundation; 2002. Available from: http://www. kidney. org/professionals/kdoqi/guidelines_ckd/bibliography. htm#267. Accessed September 09, 2013.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012; 2: 279-335.
4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17): 2038-2047.
5. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005; 365(9456): 331-340.
6. US Government. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
7. Roderick P, Roth M, Mindell J. Prevalence of chronic kidney disease in England: findings from the 2009 health survey for England. J Epidemiol Community Health. 2011; 65(Suppl I): A12.
8. Zoccali C, Kramer A, Jager K. Chronic kidney disease and end-stage renal disease a review produced to contribute to the report 'status of health in the European union: towards a healthier Europe'. NDT Plus. 2010; 3(3): 213-224.
9. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010; a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2197-2223.
10. Levin A. Identification of patients and risk factors in chronic kidney disease: evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001; 16 Suppl 7: 57-60.
11. Chadban S, Howell M, Twigg S, et al; CARI. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes. Nephrology (Carlton). 2010; 15 Suppl 1: S195-203.
12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalizations. N Engl J Med. 2004; 351(13): 1296-1305.
13. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004; 15(5): 1307-1315.
14. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardol. 2008; 52(19): 1527-1539.
15. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with aneamia; The Third national Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162(12): 1401-1408.
16. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20(9): 1501-1510.
17. Painter P, Moore G, Carlson L, et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis. 2002; 39(2): 257-265.
18. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD); a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005; 45(4): 658-666.
19. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000; 356(9224): 147-152.
20. Portolés J, Gorriz JL, Rubio E, et al; for NADIR-3 Study Group. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013; 14: 2.
21. Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalization and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton). 2009; 14(2): 240-246.
22. Locatelli F, Andrulli S, Memoli B, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006; 21(4): 991-998.
23. Vaziri ND. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? Nat Clin Pract Nephrol. 2008; 4(8): 436-445.
24. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008; 24(3): 625-637.
25. Eandi M. Erythropoiesis-stimulating agents in patients with chronic kidney disease. Rev Health Care. 2012; 3(2): 113-125.
26. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 1984; 25(2): 437-444.
27. Lonnemann G, Macdougall IC. Biosimilar epoetins in renal anaemia â current status and insights from European practice. Eur Nephrol. 2011; 5(2): 101-107.
28. Krivoshiev S, Todorov VV, Manitius J, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Curr Med Res Opin. 2008; 24(5): 1407-1415.
29. Macdougall IC. Recent advances in erythropoietic agents in renal aneamia. Semin Nephrol. 2006; 26(4): 313-318.
30. Locatelli F, Báránay P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28(6): 1346-1359.
31. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007; 49(2 Suppl 2): S12-S154.
32. Zumbreanen-Bullogh K, Babitt JL. The iron cycle in CKD: from genetics and experimental models to CKD patients. Nephrol Dial Transplant. Epub November 13, 2013.
33. Jones M, Schenkel B, Just J. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality. Int J Cardiol. 2005; 100(2): 253-265.
34. Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study). Am J Kidney Dis. 1999; 34(6): 1089-1095.
35. Evans RW. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis. Am J Kidney Dis. 1991; 18(4 Suppl 1): 62-70.
36. Painter P. The importance of exercise training in rehabilitation of patients with end-stage renal disease. Am J Kidney Dis. 1994; 24(1 Suppl 1): S2-S9; discussion S31-S32.
37. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995; 25(4): 548-554.
38. Roger SD. Biosimilars: How similar or dissimilar are they? Nephrology (Carlton). 2006; 11(4): 341-346.
39. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). London: European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP); 2010 Oct[about 8 p.] Available from: http://www. ema. europa. eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474. pdf. Accessed September 12, 2013.
40. Rossert J. EMEA guidelines on biosimilars and their clinical implications. Kidney Blood Press Res. 2007; 30 Suppl 1: 13-17.
41. Krivoshiev S, Wizemann V, Czekalsk S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010; 27(2): 105-117.
42. Triolo G; Italian Society of Nephrology. Guidelines for the treatment of aneamia in chronic renal failure. G Ital Nefrol. 2003; 20 Suppl 24: S61-S82. Italian.
43. Barosi G, Bosi A, Abbroacchio MP, et al. Key concepts and crucial issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011; 96(7): 937-942.
44. Waller CF. Biosimilars and their use in hematology and oncology. Commun Oncol. 2012; 9(6): 198-205.
45. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: Current status and future challenges. Bio Drugs. 2013; 27(3): 203-211.
46. Borges L. Different modalities of erythropoiesis stimulating agents. Port J Nephrol Hypert. 2010; 24(2): 137-145.
47. Sitte HH. Biologicals and biosimilars. Port J Nephrol Hypert. 2009; 23(2): 135-139.
48. Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following heir parenteral administration into human body. J Drug Target. 2010; 18(17): 489-498.
49. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus. 2009; 2(Suppl 1): i27-i36.
50. Casadevall N, Echardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol. 2005; 16 Suppl 1: S67-S69.
51. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant. 2005; 20 Suppl 4: iv3-iv8.
52. Abraham I, Sun D, Bagalagel A, et al. Biosimilars in 3D: Definition, development and differentiation. Bioengineered. 2013; 4(4): 203-206.
53. Ahmed I, Kaspar B, Sharma U. Biosimilars: Impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther. 2012; 34(2): 400-419.
54. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: An analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacother. 2005; 25(7): 954-962.
55. Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012; 120(26): 5111-5117.
56. Non-clinical guidelines: European Union guidelines adopted in Australia [webpage on the Internet]. Symonston: Department of Health: Therapeutic Goods Administration; 2012. Available from: http://www. tga. gov. au/industry/pm-euguidelines-adopted-nonclinical. htm#nonclinicalsimilar. Accessed Sept 10, 2013.
57. Del Vecchio L, Locatelli F. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opin Drug Saf. 2012; 11(6): 923-931.
58. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Guidelines on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. London: European Medicines Agency; 2007. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003947. pdf. Accessed September 09, 2013.
59. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency; 2006. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920. pdf. Accessed September 09, 2013.
60. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol. 2010; 85(10): 771-780.
61. European medicines Agency. Scientific discussion. London: European medicines Agency; 2007. Available from: http://www. ema. europa. eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374. pdf. Accessed September 10, 2013.
62. MP389 Immunogenicity of epoetin zeta in the treatment of renal anaemia [webpage on the internet]. Casadevall N, Kromminga A, Scigalla P. Available from: http://www. abstracts2view. com/era_archive/view. php?nu=ERA08L_1714. Accessed September 14, 2013.
63. Guidance for industry formal meetings between the FDA and biosimilar biological product sponsors or applicants [webpage on the Internet]. Silver Spring: U. S. Food and Drug Administration. Available from: http://www. fda. gov/Drugs/GuidancecomplianceRegulatory Information/Guidances/default. htm. Accessed March 2013.
64. U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Draft guidance for industry formal meetings between FDA and biosimilars biological product sponsors or applicants. Available from: http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM345649. pdf. Accessed January 8, 2014.
65. Decision memo for erythropoiesis stimulating agents (ESAs) for treatment of anemia in adults with CKD including patients on dialysis and patients not on dialysis (CAG-00413N) [webpage on the Internet]. Baltimore: Centers for Medicare and Medicaid Services (CMS); 2011. Available from: http://www. cms. gov/medicare-coverage-database/details/nca-decision-memo. aspx?NCAId=245&bc=AAAAAAAACAAAAA%3d%3d&. Accessed September 20, 2013.
66. Erythropoietin stimulating agents policies [webpage on the Internet]. Baltimore: Centers for Medicare and Medicaid Services (CMS); 2013. Available from: http://www. cms. gov/Medicare/Coverage/CoverageGenInfo/esapolicies. html. Accessed September 20, 2013.
67. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010; 116(16): 3039-3048.
68. Macdougall IC. Novel agents for anaemia management in chronic kidney disease. Europiean Nephrol. 2010; 4(1): 37-41.
69. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 2013; 27(1): 41-53.
70. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010; 21(12): 2151-2156.
71. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med. 1987; 316(2): 73-78.
72. Adamson JW, Eschbach JW. Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med. 1989; 73(272): 1093-1101.
73. Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: An update to selection for anaemia of Chronic Kidney Disease. Drugs. 2013; 73(2): 117-130.
74. Walsh G. Post-translational modifications in the context of therapeutic proteins: An introductory overview. Post-translational Modification of Protein Biopharmaceuticals. West Sussex, UK: Wiley-Blackwell. 2009: 1-14.
75. Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist. 2011; 16 Suppl 3: 19-24.
76. Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology: Effect of injection frequency on weekly dose. Int J Clin Med. 2012; 3: 598-602.
77. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012; 12(11): 1473-1485.
78. Casadevall N, Edwards IR, Felix T, et al. Pharmacovigilance and biosimilars: Considerations, needs and challenges. Expert Opinion Biol Ther. 2013; 13(7): 1039-1047.
79. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008; 25(11): 1215-1228.
80. Bachmakov I, MeiBner R, Benkenstein C. Sa423 Comparison of long-term efficacy and safety of epoetin zeta in elderly 'real-word' patients with chronic kidney disease (CKD) and renal anaemia on dialysis aged $ and, 75 years. Poster Session: Anaemia in CKD 5.
81. Bajraktar J, Lazarova B, Najdovska E, Mihajlova L. DSL-011 efficacy and safety of epoetin zeta in dialysis patients. Eur J Hosp Pharm Sci Pract. 2013; 20: A91.
82. Singh A, Saczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med. 2006; 355(20): 2085-2098.
83. Drüeke TB, Locatelli F, Clyne N, et al; for the CREATE investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355(20): 2071-2084.
84. Pfeffer MA, Burdmann EA, Chen C, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21): 2019-2032.
85. Zockali C, Abramowicz D, Cannata-Andia JB, et al. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrol Dial Transplant. 2008; 23: 2162-2166.
86. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008; 3(1): 193-199.
87. Perani L, Scolari C, Braus A, Galli E. GRP-179 switch from CERA to EPO zeta in patients with anaemia and chronic kidney disease. Eur J Hos Pharm Sci Pract. 2013; 20: A64.
88. Wiecek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis. Adv Ther. 2010; 27(12): 941-952.
89. Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf. 2012; 11(5): 819-840.
90. Retacrit: epetin zeta. Product information: Annex I. Available from: http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/000872/human_med_001031. jsp&mid=WC0b01ac058001d124. Accessed March 4, 2014.
91. Lee JS, Ha TK, Lee SJ, Lee GM. Current state and perspectives on erythropoietin production. Appl Microbiol Biotechnol. 2012; 95(6): 1405-1416.
92. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: Considerations for the healthcare provider. Curr Med Res Opin. 2012; 28(6): 1053-1058.
93. Salem L, Harvie B. Biosimilar medicines and their use: The nurse's role and responsibility. Ren Soc Aust J. 2010; 6(2): 76-80.
94. Goldsmith D, Gesualdo L. Biosimilar epoetins in nephrology-where are we now. Eur Nephrol. 2012; 6: 21-24.
95. Simoens S, Verbeken G, Huys I. Biosimilars and market access: A question of comparability and costs? Targeted Oncol. 2012; 7(4): 227-231.
96. Goldsmith D. 2009: A requiem for rHuEPOs-but should we nail down the coffin in 2010? Clin J Am Soc Nephrol. 2010; 5(5): 929-935.
97. Lopez MJ, Antonino G, Vicente I, Mejia L, Garcia P, Sanchez A. Erythropoietic factors in renal chronic disease: Economic management. Int J Clin Pharm. 2012; 34(1): 221-222.
98. Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Value Health. 2008; 11(3): A304.
99. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011; 3: 29-36.
100. Tzekova V, Mihaylov G, Elezovic I, Koytchev R; Epoetin Zeta Oncology Study Group. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin. Jul 2009; 25(7): 1689-1697.
101. Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010; 19(2): 153-159.
102. Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. 2006; 22(10): 1929-1937.
103. Keown PA, Churchill DN, Poulin-Costello M, et al. Dialysis patients treated with epoetin alfa show improved anemia symptoms; A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int. 2010; 14(2): 168-173.
104. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004; 65(3): 757-767.
105. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health. 2008; 11(1): 57-75.
106. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2008; 75(1): 15-24.
107. All Wales Medicines Strategy Group [homepage on the Internet]. Epoetin zeta (Retacrit®): Reference No. 130, final appraisal recommendation. Available from: http://www. awmsg. org/awmsgonline/app/appraisalinfo/130. Accessed March 6, 2014.